Genetic and hormonal risk factors in breast cancer

Journal of the National Cancer Institute

Volumn 92, Issue 14, 2000, Pages 1126-1135

  Martin, Anne Marie ^a   Weber, Barbara L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ANDROGEN RECEPTOR; ETHOXYRESORUFIN DEETHYLASE; GLUTATHIONE TRANSFERASE;

ATAXIA TELANGIECTASIA; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COWDEN SYNDROME; GENE MUTATION; GENETIC RISK; HUMAN; MUIR TORRE SYNDROME; NONHUMAN; OBESITY; PENETRANCE; PEUTZ JEGHERS SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE;

EID: 0034686619     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.14.1126     Document Type: Review

References (166)

1. Breast cancer: Magnitude of the problem and descriptive epidemiology
2. The genetic attributable risk of breast and ovarian cancer
3. Endogenous sex hormone levels and breast cancer risk
4. The hormonal basis of breast cancer
5. Epidemiologic analysis of breast and gynecologic cancers
6. Menopause and breast cancer risk
7. Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk
8. Projected changes in breast cancer incidence due to the trend toward delayed childbearing
9. Physical exercise and reduced risk of breast cancer in young women
10. Risk factors for breast cancer in Chinese women in Shanghai
11. Estrogen replacement therapy and breast cancer
12. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer
13. Age at first birth and breast cancer risk
14. Characteristics that predict risk of breast cancer before and after the menopause
15. Obesity and breast cancer risk
16. Breast cancer and other second neoplasms after childhood Hodgkin's disease
17. Second cancers following pediatric Hodgkin's disease
18. Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer
19. Incidence of female breast cancer among atomic bomb survivors, 1950-1985
20. Current perspectives on radiation-induced breast cancer
21. Breast cancer risk and alcohol consumption: Results from a large case-control study
22. Alcohol and breast cancer: A cohort study
23. Alcohol consumption and breast cancer risk in Denmark
24. Associations of alcohol, height, and reproductive factors with serum hormone concentrations in postmenopausal Japanese women. Steroid hormones in Japanese postmenopausal women
25. Breast cancer: Weighing the evidence for a promoting role of dietary fat
26. A metaanalysis of studies of dietary fat and breast cancer risk
27. Well-done meat intake and the risk of breast cancer
28. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, welldone meat intake, and breast cancer risk
29. Genetic epidemiology of breast cancer: Segregation analysis of 200 Danish pedigrees
30. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
31. Linkage of early-onset familial breast cancer to chromosome 17q21
32. Familial breast-ovarian cancer locus on chromosome 17q12-q23
33. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium
34. Inherited susceptibility to breast cancer
35. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
36. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium
37. BRCA1 mutations in young women with breast cancer
38. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
39. Familial clustering of colon, breast, uterine, and ovarian cancers as assessed by family history
40. Familial breast cancer risks. Effects of prostate and other cancers
41. Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer
42. BRCA1 protein products: Functional motifs
43. From BRCA1 to RAP1: A widespread BRCT module closely associated with DNA repair
44. Mouse Brca1: Localization sequence analysis and identification of evolutionarily conserved domains
45. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins
46. BRCA1 mutations in primary breast and ovarian carcinomas
47. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer
48. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families
49. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families
50. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core
51. BRCA1 mutations in Ashkenazi Jewish women
52. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
53. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
54. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: A genetic study of 15 185delAG-mutation kindreds
55. The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim
56. Prevalence of BRCA1 and BRCA2 Jewish mutations in Spanish breast cancer patients
57. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer
58. Germline BRCA1 185delAG mutations in Jewish women with breast cancer
59. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics
60. BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in Scotland
61. Population genetics of BRCA1 and BRCA2
62. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families
63. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
64. A common BRCA1 mutation in Norwegian breast and ovarian cancer families?
65. A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2
66. Evidence of a founder mutation in Scotland
67. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
68. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions
69. An Alu-mediated 6-kb duplication in the BRCA1 gene: A new founder mutation?
70. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome
71. BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis
72. BRCA1 is a component of the RNA polymerase II holoenzyme
73. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A
74. Association of BRCA1 with Rad51 in mitotic and meiotic cells
75. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway
76. BRCA1 is associated with the centrosome during mitosis
77. 2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficiant cells
78. Cytoplasmic accumulation of cyclin B1 in human cells: Association with a detergent-resistant compartment and with the centrosome
79. 2/M and enters vesicles at anaphase
80. Cell cycle independent interaction of CDC2 with the centrosome, which is associated with the nuclear matrix-intermediate filament scaffold
81. Both viral (adenovirus E1B) and cellular (hsp 70, p53) components interact with centrosomes
82. Abnormal centrosome amplification in the absence of p53
83. Centrosome hyperamplification in human cancer: Chromosome instability induced by p53 mutation and/or Mdm2 overexpression
84. Induction of apoptosis by the tumor suppressor protein BRCA1
85. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1
86. BRCA1 required for transcription-coupled repair of oxidative DNA damage
87. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair
88. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
89. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
90. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium
91. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families
92. Cancer risks in BRCA2 mutation carriers
93. Identification of the breast cancer susceptibility gene BRCA2
94. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds
95. The BRC repeats are conserved in mammalian BRCA2 proteins
96. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2
97. BRCA2 germline mutations in male breast cancer cases and breast cancer families
98. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer
99. BRCA2 mutations in primary breast and ovarian cancers
100. Mutation analysis in the BRCA2 gene in primary breast cancers
101. Mutations of the BRCA2 gene in ovarian carcinomas
102. Inherited BRCA2 mutation associated with high grade breast cancer
103. BRCA2 in American families with four or more cases of breast or ovarian cancer: Recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2
104. BRCA2 germline mutations in Japanese breast cancer families
105. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%
106. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients
107. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients
108. A low proportion of BRCA2 mutations in Finnish breast cancer families
109. Rad51 protein involved in repair and recombination in S. cerevisiae is a RecA-like protein
110. Murine Brca2: Sequence, map position, and expression pattern
111. Characterization of the rat and mouse homologues of the BRCA2 breast cancer susceptibility gene
112. Nuclear location and cell cycle regulation of the BRCA2 protein
113. Cell cycle control of BRCA2
114. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?
115. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
116. Screening for germ line TP53 mutations in breast cancer patients
117. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase
118. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome
119. Increased risk for cancer in patients with the Peutz-Jeghers syndrome
120. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer
121. Cowden syndrome
122. The Cowden syndrome: A clinical and genetic study in 21 patients
123. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
124. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
125. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta
126. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
127. Localization of the gene for Cowden disease to chromosome 10q22-23
128. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
129. Candidate gene analysis and preliminary genomic search results for mapping of non-BRCA1/2 breast cancer genes
130. The role of MMAC1 mutations in early-onset breast cancer: Causative in association with Cowden syndrome and excluded in BRCA1-negative cases
131. Inherited mutations in PTEN that are associated with breast cancer, cowden disease, and juvenile polyposis
132. Polymorphisms in PTEN in breast cancer families
133. The Muir-Torre syndrome: A 25-year retrospect
134. Association of sebaceous gland tumors and internal malignancy: The Muir-Torre syndrome
135. Breast and other cancers in families with ataxia-telangiectasia
136. Incidence of cancer in 161 families affected by ataxia-telangiectasia
137. ATM mutations in cancer families
138. Heterozygous ATM mutations do not contribute to early onset of breast cancer
139. Absence of linkage to the ataxia telangiectasia locus in familial breast cancer
140. Molecular genotyping shows that ataxiatelangiectasia heterozygotes are predisposed to breast cancer
141. The role of ataxia-telangiectasia heterozygotes in familial breast cancer
142. Cancer risks in A-T heterozygotes
143. Linkage analysis of DRD2, a marker linked to the ataxia-telangiectasia gene, in 64 families with premenopausal bilateral breast cancer
144. Recent advances in breast cancer biology
145. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer
146. 17β-estradiol 2- and 4-hydroxylation catalyzed by rat hepatic cytochrome P-450: Roles of individual forms, inductive effects, developmental patterns, and alterations by gonadectomy and hormone replacement
147. Functional significance of different human CYP1A1 genotypes
148. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women
149. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk
150. Polychlorinated biphenyls, cytochrome P4501A1 polymorphism, and postmenopausal breast cancer risk
151. Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue
152. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility
153. Modifications of familial breast cancer penetrance by glutathione-S-transferase genotypes
154. Glutathione-S-transferase (GSTM1) genetic polymorphisms do not affect human breast cancer risk, regardless of dietary antioxidants
155. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk
156. Association of breast cancer incidence with NAT2 genotype and smoking in BRCA1 mutation carriers
157. Breast cancer risk, meat consumption and N-acetyltransferase (NAT2) genetic polymorphisms
158. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps
159. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat
160. Rodent models for the study of etiology, prevention and treatment of breast cancer
161. The genetic components of susceptibility to breast cancer in the rat
162. Genetic identification of Mcs-1, a rat mammary carcinoma suppressor gene
163. Genetic identification of multiple loci that control breast cancer susceptibility in the rat
164. Use of recombinant congenic and congenic strains of NOD mice to identify a new insulin-dependent diabetes resistance gene
165. Prospects for whole-genome linkage disequilibrium mapping of common disease genes
166. The essence of SNPs